EPCAM and neoplasm: Targeting EpCAM has shown promise, but due to the environmental issues, as well as the requirement for sufficient numbers of antibodies to surround each cancer cell in order to provoke an immune response from CD16-positive cells, the next wave of antibodies sought to harness the immune system by bringing the immune cells into close proximity with the tumour cells [35].